Approval · Notice of Compliance 25770 · 2021
RASILEZ: Notice of Compliance 25770
Issued April 30, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25770
- Date
- April 30, 2021
- Company
- Noden Pharma DacDublin, Dublin, Ireland
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To revise the package labels and insert du to changes in package dimensions
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RASILEZ | Not yet assigned | — |
Medicinal ingredients
- ALISKIREN FUMARATE 150 MG per MG
- ALISKIREN FUMARATE 300 MG per MG